Darwin products are investigational diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial use.
Darwin Biosciences specializes in
saliva-based diagnostic tests for infectious disease.
We are developing diagnostics that can identify people who are asymptomatic or pre-symptomatic for common infectious diseases, including COVID-19. Some of our products are being designed for clinical use. Others are expected to be hand-held and self-administered, so that people can monitor their own health at home or when reporting for work at venues where vulnerable people (i.e. nursing homes, hospitals) or many people (delivery personnel, airport employees) are being served.
In the news
CU Boulder Today, Senior Science Editor, Lisa Marshall, breaks down the Darwin Biosciences presentation that took first place at the University of Colorado 2020 New Venture Challenge . Darwin Biosciences was awarded $30,000 and an additional $25,000 in investment...
BizWest and Daily Camera journalist, Lucas High, covers the latest success for the team at Darwin Biosciences. Darwin took first place at the University of Colorado 2020 New Venture Challenge pitch, Tuesday, April 7. Darwin Biosciences was awarded $30,000 and an...
Boulder, CO, USA